01—Abstract
Summary
Summary of the 10-Q filed August 31, 2023. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported total net revenue of $1,672 milliona for the third quarter of fiscal year 2023, a 3% decrease compared to the prior year.
For the first nine months of fiscal year 2023, revenue increased by 3% to $5,145 millionb. The company experienced a significant decline in income from operations, which was heavily impacted by a substantial asset impairment charge of $277 million related to the shutdown of its Resolution Bioscience business.
Despite the revenue dip in the current quarter, driven by weaker demand in the Life Sciences and Applied Markets segment, particularly in Asia Pacific, the company saw growth in its Agilent CrossLab segment. Looking ahead, Agilent anticipates a challenging macroeconomic environment and customer capital expenditure pressures, especially in China, but remains optimistic about long-term growth opportunities across its key markets.
02—Key points
Key Highlights
- Q3 FY2023 Net Revenue: $1,672 million, down 3% year-over-year.
- Nine Months FY2023 Net Revenue: $5,145 million, up 3% year-over-year.
- Significant Asset Impairment: $277 million charge due to the shutdown of the Resolution Bioscience business, impacting profitability.
- Income from Operations Decline: Decreased 68% in Q3 FY2023 due to impairment charges, and 18% year-to-date.
- Segment Performance Mix: Life Sciences and Applied Markets revenue declined 9% in Q3, while Agilent CrossLab revenue grew 10%.
- Strong Cash Flow from Operations: $1,256 million generated in the first nine months of FY2023, up from $864 million in the prior year.
- Active Share Repurchase Program: Approximately $1.604 billion remaining authorization under the 2023 repurchase program.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2023, Agilent Technologies, Inc. kept $0.07.
- Revenue$1.67B100.0%
- Cost of revenue−$1.01B60.6%
- Gross profit$658.0M39.4%
- Operating costs−$525.0M31.4%
- Operating income$133.0M8.0%
- Interest, other & tax−$22.0M1.3%
- Net income$111.0M6.6%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2023filed August 31, 2023Financial Statements
Q3 FY2023 against Q3 FY2022
| Line item | Q3 FY2023Q3 FY2022 | Change |
|---|---|---|
| Revenue | $1.67B$1.72B | −2.7% |
| Cost of Revenue | $1.01B$779.00M | +30.2% |
| Gross Profit | $658.00M$939.00M | −29.9% |
| R&D Expenses | $118.00M$116.00M | +1.7% |
| SG&A Expenses | $407.00M$412.00M | −1.2% |
| Operating Expenses | $1.54B$1.31B | +17.8% |
| Operating Income | $133.00M$411.00M | −67.6% |
| Interest Expense | $24.00M$19.00M | +26.3% |
| Net Income | $111.00M$329.00M | −66.3% |
| EPS (Basic) | $0.38$1.10 | −65.5% |
| EPS (Diluted) | $0.38$1.10 | −65.5% |
| Shares Outstanding (Basic) | 294.00M298.00M | −1.3% |
| Shares Outstanding (Diluted) | 295.00M299.00M | −1.3% |
05—Questions
Frequently Asked Questions
What caused the significant decrease in net income and income from operations in the third quarter?
The significant decrease in net income and income from operations was primarily due to a substantial asset impairment charge of $277 million related to the decision to shut down the Resolution Bioscience business. This charge impacted the company's profitability for the quarter and the first nine months of the fiscal year.
How did the company's different business segments perform?
Performance varied across segments. The Life Sciences and Applied Markets segment saw a 9% revenue decrease in Q3 FY2023, impacted by weaker demand in certain markets and regions like Asia Pacific. In contrast, the Agilent CrossLab segment showed robust growth, with revenue increasing by 10% in Q3 FY2023, driven by strong demand for its services across all end markets. The Diagnostics and Genomics segment also experienced modest growth.
What is the outlook for the company given the current macroeconomic environment?
Agilent anticipates a challenging macroeconomic environment with pressure on customer capital expenditures, particularly in China. However, the company remains optimistic about its long-term growth prospects across all its key end markets, supported by its differentiated product solutions and focus on customer experience and productivity.
What is the company's strategy regarding capital allocation?
Agilent continues to focus on balanced capital allocation. This includes returning capital to shareholders through dividends and significant share repurchases, with approximately $1.604 billion remaining authorization under its 2023 repurchase program. The company also continues to invest in its manufacturing capacity, notably for nucleic acid-based therapeutics.
06—Continue